Global Artemisinin Combination Therapy Market Size study, by Combination Therapy Type, and Regional Forecasts 2022-2032

The Global Artemisinin Combination Therapy (ACT) Market is valued at approximately USD 1.2 billion in 2023 and is projected to grow at a steady CAGR of more than 8.20% over the forecast period 2024-2032. ACT has long stood as a frontline defense against malaria-a disease that disproportionately burdens low- and middle-income countries with staggering social and economic implications. By pairing artemisinin derivatives with partner drugs that have longer half-lives, ACT offers rapid parasite clearance and minimizes resistance development, making it the gold standard for Plasmodium falciparum treatment. As efforts intensify to meet WHO's global malaria eradication roadmap, ACT continues to be at the heart of national and cross-border antimalarial strategies.

This market's upward trajectory is being driven by several catalytic forces: rising malaria incidence in tropical and subtropical regions, ongoing global health campaigns like the Global Fund and PMI, and increasing government procurement of artemisinin-based drugs through public-private partnerships. The push for universal healthcare coverage in malaria-endemic regions has also boosted demand for fixed-dose combination therapies that simplify dosing regimens and ensure better patient adherence. At the same time, pharmaceutical companies are working closely with NGOs and policy-makers to strengthen drug affordability, distribution logistics, and diagnostic integration-particularly in Africa and parts of Southeast Asia.

However, despite these gains, the market is not immune to challenges. Artemisinin resistance, first documented in Southeast Asia, remains a looming threat to global malaria control efforts. The volatility of raw artemisinin supply due to agricultural dependency and climatic variability creates significant price instability. Moreover, there are substantial regulatory, infrastructural, and funding constraints that hinder access to ACTs in rural or conflict-affected zones. Nevertheless, players in the market are proactively exploring synthetic artemisinin production, next-generation combination regimens, and pediatric-specific formulations to circumvent existing barriers.

Technological and clinical innovations are reshaping the competitive dynamics of the ACT landscape. Several pharmaceutical manufacturers are adopting advanced process chemistry to reduce production costs and improve shelf stability of ACTs, making them more viable for remote storage and transportation. Increasing clinical trials focused on triple-drug therapies are expected to mitigate resistance risk and extend the efficacy lifespan of artemisinin-based combinations. Additionally, international donor coalitions are facilitating pooled procurement programs and regional manufacturing hubs to scale up local production capacities and reduce dependency on import-heavy supply chains.

Regionally, Sub-Saharan Africa continues to account for the lion's share of demand, driven by high malaria transmission rates and a supportive donor ecosystem. Nigeria, DRC, and Uganda are particularly aggressive in national rollout of ACTs. Asia Pacific follows, with India and Myanmar adopting robust treatment protocols and surveillance systems. Latin America, while facing relatively lower malaria prevalence, is adopting ACT as part of elimination efforts in Amazon Basin countries. Meanwhile, the Middle East and Europe play critical roles in financing and R&D, with North America contributing through policy advisory, funding, and strategic stockpiling for epidemic responses.

Major market player included in this report are:

• Cipla Inc.
• Novartis AG
• Sanofi S.A.
• Guilin Pharmaceutical Co. Ltd
• Ipca Laboratories Ltd.
• Strides Pharma Science Limited
• Ajanta Pharma Limited
• Mylan Laboratories Ltd.
• Macleods Pharmaceuticals Ltd.
• Fosun Pharma
• Artepharm Co., Ltd.
• KPC Pharmaceuticals
• Amneal Pharmaceuticals Inc.
• Hikma Pharmaceuticals PLC
• Zydus Lifesciences Ltd.

The detailed segments and sub-segment of the market are explained below:

By Combination Therapy Type

• Artemether-Lumefantrine
• Artesunate-Amodiaquine
• Artesunate-Pyronaridine
• Artesunate-Sulfadoxine-Pyrimethamine
• Other Combination Therapy Types

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:

• Historical Year - 2022
• Base Year - 2023
• Forecast Period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.